

11 October 2021

Osprey Medical's DyeVert™ Technology Featured at Prominent Italian Society of Interventional Cardiology Scientific Meeting

Minnesota, United States and Melbourne, Australia – 11 October 2021 – Osprey Medical, Inc. (ASX:OSP) (**Osprey or the Company**) is pleased to announce their DyeVert™ technology has been featured by strategic partner GE Healthcare in the Italian Society of Interventional Cardiology (GISE) meeting in Italy, Milan from 5th- 8th October 2021.

GE Healthcare's booth featured the DyeVert System used for preventing Contrast-Induced Acute Kidney Injury (AKI) by reducing contrast delivered to patients undergoing coronary and peripheral angiography.

Alongside this, DyeVert was featured in a scientific session focused on how to manage patients suffering from STEMI (heart attack) and CKD (kidney disease) (eGFR < 30 ml/min) to help manage the risk of AKI. A presentation for Nurses & Technicians was also held, titled '*Correlation between contrast medium and AKI in today's landscape of interventional cardiology*' highlighting the advantages of Osprey's technology and importance of renal protection with the DyeVert System.

Prof. Paolo Calabro the Director of the Cardio-Vascular Department at Sant'Anna and San Sebastiano Hospital in Caserta Italy presented complex heart procedures in patient at high risk of AKI, highlighting the importance of the DyeVert System use in reducing AKI in high-risk patients. Osprey's DyeVert System reduces contrast delivered to patients while maintaining image quality in a self-adjusting, easy-to-use design that monitors dye usage. The DyeVert system is CE mark cleared for contrast reduction and real-time monitoring of dye dose to the patients throughout the procedure.

Additionally, an abstract titled "*Preliminary findings of the DAVIDS registry (Dyevert to AVoid unnecessary contrast media Delivery during PCI Sanremo registry)" was presented in a poster at the GISE. AKI is a percutaneous coronary intervention's (PCI) feared complication, linked to increased morbidity and mortality. In this study, data collected from 48 patients by Sanremo Hospital in Sanremo, Italy showed significant reduction in AKI through a 40% reduction in contrast volume without impairing angiographic image quality using Osprey's DyeVert Power XT System.*

Osprey Medical's President and CEO, Mike McCormick, said: "We are very pleased with the high exposure and clinical evidence that was reported at the GISE meeting in Italy. Italy is one of Osprey's largest markets in Europe through our GE partnership. As COVID restrictions ease across Europe, GE Healthcare has ramped up marketing efforts around AKI reduction, promoting DyeVert technology as part of the solution. This was a very successful scientific meeting for Osprey Medical and provided us with important exposure to the physicians who are ultimately the end users of our technology."

This release dated 11 October 2021 has been authorised for lodgement to ASX by Mike McCormick, CEO.

– ENDS –

Contact details:**Osprey Medical**

Doug Schoenberg

VP of Marketing

T: +1 (952) 955 8230

dschoenberg@ospreymed.com

Investors

Prash Jitendran

Vesparum Capital

T: +61 3 8582 4800

ospreymed@vesparum.com

Media Relations

Ciara Byrne

Mana Communications

T: +61 41 3519 430

cbyrne@manacommunications.com

About Osprey Medical (ASX: OSP)

Osprey Medical's vision is to make heart imaging procedures safer for patients with poor kidney function. The amount of dye (contrast) used during angiographic imaging procedures increases the patient's risk for dye-related kidney damage known as Contrast-Induced Acute Kidney Injury (CI-AKI). The Company's core technologies originated from research conducted by Dr David Kaye at Melbourne's Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage and monitor the dose of dye real time throughout the procedure. The Company's DyeVert™ System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design that monitors dye usage. Osprey Medical's Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control (including but not limited to the COVID-19 pandemic), subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Given the current uncertainties regarding the impact of the COVID-19 on the trading conditions impacting the Company, the financial markets and the health services world-wide, investors are cautioned not to place undue reliance on the current trading outlook.

Osprey does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Osprey may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Foreign Ownership Restriction

Osprey's CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of Osprey's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.